Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting
27.11.2019 14:00:00 EET | Business Wire | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.
“We look forward to sharing progress on our lead drug candidate for the treatment of KCNQ2 epileptic encephalopathy as we advance the understanding of ion channel activators and the important role they play in epilepsy and other neurological conditions with high unmet need,” said Michael Bozik, M.D., Chief Executive Officer of Knopp Biosciences.
Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and smooth muscle conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.
Details related to Knopp Biosciences’ AES abstracts and poster presentations can be found in the table below.
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.
|
Abstract Title |
Abstract Number / Presentation Details |
|
Discovery and Characterization of KB-3061: A Potent Kv7.2/7.3 Ion Channel Activator for the Treatment of KCNQ2-Neonatal Epileptic Encephalopathy |
Abstract 3.045: Poster Presentation
|
|
KB-3061 is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro
|
Abstract 3.047: Poster Presentation
|
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is in Phase 2 clinical trials for severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.
Knopp's Kv7 research is supported under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005157/en/
Contact information
Media inquiries:
Kate Coyle
kate.coyle@icrinc.com
203-682-8210
Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
G+D Launches AI Hub in Montréal to Advance Secure AI for Critical Infrastructure16.6.2026 14:30:00 EEST | Press release
Global SecurityTech company Giesecke+Devrient (G+D) today announced the launch of its AI Hub in Montréal. Located at Mila, the hub is at the heart of G+D’s Global Center of Excellence for AI. It will develop AI solutions for security-critical environments, including authentication, cybersecurity for digital infrastructures, secure payment and transaction AI, and group-wide internal AI projects — where security, privacy and regulatory compliance are paramount. G+D has invested approximately 40 million CAD (€25 million) in Canada over the past decade in infrastructure, security modernization, and digital transformation and will invest over 80 million CAD (€50 million) in the new AI Hub over the next five years, supporting around 60 AI specialists, researchers, and product specialists. First projects already started include AI-enabled insights on eSIM anomalies, AI tracking and logistics solutions, and a banking assistant. G+D selected Montréal for the hub because of its strong AI ecosyst
Lenovo Tab Plus Gen 2 Delivers a Smarter, More Immersive Entertainment Experience16.6.2026 14:01:00 EEST | Press release
Today Lenovo™ introduced the Tab Plus Gen 2, the next generation of its tablet created for the increasingly fluid ways people move between media consumption, multitasking, and shared experiences. With upgrades spanning audio, visuals, versatility, and intelligent features, it expands the role of the tablet across a broader range of activities and environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616736263/en/ “Entertainment today isn’t tied to a single place or routine,” said Tony Chen, Vice President of Tablets, Intelligent Devices Group, Lenovo. “People are moving seamlessly between work, travel, and downtime, and they expect their devices to move just as naturally with them. With the Lenovo Tab Plus Gen 2, we created a device that keeps up with that rhythm, giving users the freedom to enjoy content on their terms.” Sound That Fills the Space Whether watching movies, streaming shows, or listening to music, us
Aurora Solar Adds Integrated Storage Modeling to HelioScope, Uniting Commercial Solar Design, Storage, and Financial Analysis in One Solution16.6.2026 13:00:00 EEST | Press release
Aurora Solar, the leading global platform for solar sales and design, today announced the addition of integrated storage modeling to HelioScope. This new feature empowers users to size storage, model performance, and run the financial case in the same place they design the system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616352623/en/ A preview of how storage modeling is integrated into the design workflow in HelioScope for fast iteration and optimization of solar-plus-storage projects What once required three tools — design, storage modeling, financials — now happens in one solution, from layout to a lender-ready output developers can take straight into financing. When a client asks what a bigger battery does to the economics, the answer takes minutes, not days. "The solar market is being tested right now, and the companies that come out ahead will be the ones that make their teams faster and their numbers more def
Dubai Chambers Organises Open Dialogue in London to Showcase Dubai’s Competitive Advantages as a Global Business Hub16.6.2026 12:25:00 EEST | Press release
Dubai Chambers organised an open dialogue in London in cooperation with the London Chamber of Commerce and Industry (LCCI) aimed at showcasing Dubai’s competitive advantages as a global business hub to a group of leading British investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616827193/en/ H.E. Mohammad Ali Rashed Lootah addresses the audience during the event (Photo: AETOSWire) The event was attended by His Excellency Mohammad Ali Rashed Lootah, President and CEO of Dubai Chambers, together with UK business leaders. Discussions highlighted the key investment opportunities Dubai offers across diverse sectors, as well as the city’s advantages as a hub for the expansion of British companies in the region and globally. The session also outlined the comprehensive support provided by Dubai Chambers to UK investors to ensure the smooth establishment and growth of their businesses in Dubai. The discussions explored how
NIQ and Unlimitail Collaborate to Deliver the Next Generation of Omnichannel Retail Media Insights & Measurement Across Retailers and Countries16.6.2026 12:00:00 EEST | Press release
Retail media investment is accelerating globally, with 67% of CMOs planning to increase spending on retail media networks (RMNs) in 2026. Yet only 53% believe today's RMNs provide adequate measurement and attribution capabilities, highlighting a critical gap in proving true business impact across retailers and markets.* Today, NIQ (NYSE: NIQ), a leading consumer intelligence company, and Unlimitail, a leading retail media network, announced a strategic collaboration designed to help brands and retailers unlock a new era of retail media accountability through advanced measurement, consumer insights, interoperable data infrastructure, and AI-powered analytics. This collaboration will combine Unlimitail's extensive retail media network, which spans 21 countries, 35 retailers, more than 120 retailer websites, and over 250 million loyalty cardholders, with NIQ's industry-leading measurement, analytics, and consumer intelligence capabilities. Together, the companies will help advertisers mov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom